04:24 AM EST, 03/06/2024 (MT Newswires) -- Evotec SE ( EVO ) and biotech venture capital firm Claris Ventures said Wednesday they had agreed to streamline proposals from biotech companies into clinical trials.

Financial terms of the agreement were not disclosed.

Claris's portfolio includes nine European biotech firms with treatments approaching clinical trials. Under the terms of the new agreement, Claris's portfolio companies will have access to Evotec's research and development and clinical testing platform.

Evotec already provides such services to Claris portfolio company IAMA Therapeutics, which develops potential brain disorder treatments.